Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
It is a novel oral NLRP3 inflammasome inhibitor
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Subscribe To Our Newsletter & Stay Updated
